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Objective: Infants with chronic lung disease of infancy (CLDI) are at high risk for severe 
respiratory syncytial virus (RSV) illness requiring hospitalization. Palivizumab was first licensed 
in 1998 for the prevention of RSV disease in high-risk infants, including those with CLDI. We 
performed a retrospective cohort study of all hospitalized children with CLDI aged ,2 years 
between 1998 and 2008 in the USA to determine trends in rates of hospitalizations due to RSV 
(RSVH) since the launch of palivizumab.
Materials and methods: Data from the United States National Hospital Discharge Survey, a 
multistage systematic survey sample of US hospitals, were assembled. We defined RSVH using 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes of 079.6 (RSV), 466.11 (acute bronchiolitis due to RSV), and 480.1 (pneumonia due 
to RSV). Quarterly rates of RSVH were assessed for children with CLDI (ICD-9-CM code 
770.7) and calculated between 1998 and 2008. Because RSV may be miscoded, the analysis 
was repeated after expanding the definition of RSVH to include all acute bronchitis and acute 
bronchiolitis (ABH) (ICD-9-CM = 466). Trends were described using linear regression with 
seasonal indicators included in the model.
Results: On average, about 966 RSVH (range 98–1373 RSVH) per year were found for chil-
dren ,2 years with CLDI in the USA between 1998 and 2008. Over the 11-year period, the 
predicted rate of RSVH statistically significantly decreased by 48% (from 93.78 to 49.06 RSVH 
per 1 million children) (P = 0.013). Addition of ABH resulted in a nonstatisically significant 
decrease of 32% over the 10-year period (P = 0.102).
Conclusion: These results suggest that there has been a decrease in the rate of RSVH in infants 
with CLDI between 1998 and 2008. The reasons for this decrease may include improved neo-
natal intensive care unit and outpatient management of CLDI, and possibly increased use of 
palivizumab in this high-risk population.
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Introduction
Chronic lung disease of infancy (CLDI), as defined by the American Thoracic 
Society,1 is “a heterogeneous group of respiratory diseases of infancy that usually 
evolves from an acute respiratory disorder experienced by a newborn infant.” CLDI 
occurs most frequently in infants born prematurely and is the most common form 
of chronic lung disease of infancy in the USA.2 Infants with CLDI are at high risk 
for re-hospitalization in the first 2 years of life, and in particular, are at high risk for 
RSVH (hospitalization due to lower respiratory tract infection due to respiratory 
syncytial virus [RSV]).3Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Palivizumab (MedImmune, LLC, Gaithersburg, MD), 
a humanized monoclonal antibody developed for the preven-
tion of RSV disease in high-risk infants, has been recom-
mended since 1998 for infants and young children with CLDI 
who are #24 months of age.4 To our knowledge, no studies 
have evaluated RSV/bronchiolitis hospitalizations in infants 
and children with CLDI after palivizumab became available. 
We analyzed data from the United States National Hospital 
Discharge Survey (NHDS) to examine temporal trends in 
RSVHs among children younger than 2 years following the 
introduction of palivizumab.
Materials and methods
Data from the NHDS for children younger than 2 years 
with a diagnosis of CLDI were analyzed to examine the 
rate of hospitalizations for CLDI (CLDIH) that were also 
associated with RSV for each year between 1998 and 2008. 
US population values for children ,2 years used to calcu-
late yearly rates were available through CDC WONDER.5 
Because testing for RSV is not consistently performed 
in the hospital setting, we repeated the analyses with an 
expanded definition of RSV that included acute bronchitis 
and bronchiolitis.
The NHDS is the largest available nationally repre-
sentative survey of inpatient hospitalizations. NHDS has 
been collecting inpatient discharge records from non-
federal short-stay hospitals annually since 1965. Patient 
discharges from hospitals having six or more beds for 
inpatient use are included in the survey. A three-stage 
probability design based on geographic areas, hospitals, 
and discharges is utilized to select sample data. Data are 
weighted to produce national estimates. Variables collected 
at each discharge included patient demographics (age, sex, 
race, marital status), hospital characteristics (geographic 
location, number of beds), and inpatient hospitalization 
diagnoses (up to seven ICD-9-coded diagnoses), days of 
hospitalized care, patient disposition, month, day, and year 
of discharge, primary and secondary expected source of 
payment, and type of admission and procedures. Patient 
identification information is removed so that all data are 
anonymous.6
Hospital discharges with $1 diagnosis coded to ICD-9 
770.7 were considered CLDIHs. This code covers CLDI aris-
ing in the perinatal period, and includes bronchopulmonary 
dysplasia, interstitial pulmonary fibrosis of prematurity, and 
Wilson–Mikity syndrome.7 RSV associated with CLDIH 
(RSVH) was defined as a hospital discharge with a diagnosis 
code of 770.7 (chronic lung disease) and a diagnosis code 
of 079.6 (RSV), 466.11 (acute bronchiolitis due to RSV) 
or 480.1 (pneumonia due to RSV). Although RSV coding 
was first introduced in 1996, the current study analyzed data 
starting in 1998 to allow enough time to ensure wide hospital 
adoption of the new RSV codes.
Testing for RSV is often not performed in the hospital 
setting and presumptive RSV lower respiratory infections 
may be miscoded. We therefore expanded our definition of 
RSVH to include all acute bronchitis and acute bronchiolitis 
hospitalizations (ABHs) and conducted additional analyses 
based on this expanded definition of disease (RSVH/ABH). 
Specifically, a hospital discharge with an ICD-9 diagnosis 
code of 770.7 (CLDI) and a diagnosis code of either 079.6 
(RSV), or 480.1 (pneumonia due to RSV) or any 466 (acute 
bronchitis and bronchiolitis) were considered together as 
RSVH/ABH. ICD-9 diagnosis code 466 includes 466.0 
(acute bronchitis), 466.1 (acute bronchiolitis), 466.11 (acute 
bronchiolitis due to RSV), and 466.19 (acute bronchiolitis 
due to other organisms).
Analyses were limited to hospitalization discharges that 
occurred prior to a child with CLDIH turning 2 years old. 
Simple descriptive statistics were calculated. Quarterly rates 
of RSVH (or RSVH/ABH) among children with CLDI were 
calculated by dividing the number of RSVH (or RSVH/
ABH) among children with CLDI by the total number of 
children for that year. Data were first transformed using 
the square root to correct for heteroscedasticity.8 Indicator 
variables corresponding to each quarter of the year were 
created to control for seasonality.9 Trends were described 
using linear regression. All statistical analyses were per-
formed using Statistical Analysis Software version 9.1 (SAS 
Institute Inc, Cary, NC) and Minitab Statistical Software 
(Minitab Inc, Release 14, State College, PA). The figures 
displaying actual rates versus predicated rates of RSVH 
and RSVH/ABH (Figures 1 and 2) were produced using 
Minitab Statistical Software Release 14 (Minitab Inc, State 
College, PA).
Results
From 1998 to 2008, there were 10,622 CLDI children 
with RSVH. The primary hospitalization for RSVH (first 
diagnosis code of the up to 7 discharge diagnosis codes 
listed) was acute bronchitis and bronchiolitis (ICD-9 = 466) 
(60%) for most of the CLDI children followed by viral 
pneumonia (ICD-9 = 480) (17%), asthma (ICD-9 = 493) 
(5%), pneumonia (ICD-9 = 486) (3%), and other condi-
tions (15%). Forty-five percent of RSVHs were found in 
children .6 months to 2 years. RSVH was more common Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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among males (65%) (Table 1). By race, 44% of RSVH 
occurred among whites, compared with 25% among African 
Americans and 31% among others/unknown. By region, 
more RSVHs occurred in the Western part of the USA 
(39%) than in the Midwest (22%) or Northeast (23%), with 
the lowest percentage of RSVHs occurring in the South 
(16%). Medicaid was the expected source of payment for 
the majority of RSVHs (64%).
RSVH/ABH included 23,199 hospitalizations, of which 
21,780 hospitalizations were due to ICD-9 code 466. Among 
those with ICD-9 code 466, 2% were coded as acute bronchi-
tis (ICD-9 = 466.0), 42% were coded as acute bronchiolitis 
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Figure 1 The rates of respiratory syncytial virus hospitalizations among patients younger than 2 years with CLDi by quarter from 1998 to 2008.  Actual rates and predicted 
rates from time series regression model.
Abbreviations: CLDi, chronic lung disease of infancy; rsV, respiratory syncytial virus; rsVh, respiratory syncitial virus hospitalization.
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Figure 2 The rates of respiratory syncytial virus and AB and bronchiolitis hospitalizations among patients younger than 2 years with CLDi by quarter from 1998 to 2008. 
Actual rates and predicted rates from time series regression model. 
Abbreviations: AB, acute bronchitis; CLDi, chronic lung disease of infancy; rsV, respiratory syncytial virus; rsVh, respiratory syncitial virus hospitalization.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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due to respiratory syncitial virus (ICD-9 = 466.11), and 56% 
were coded as acute bronchiolitis due to other infectious 
organisms (ICD-9 = 466.19). The demographics for patients 
with RSVH/ABH were similar to those patients with RSVH 
(Table 1).
The average annual number of CLDIH was 22,937 (range 
17,169–26,130) and the mean annual number of RSVH was 
966 (range 98–1373) (Figure 3). The number of CLDIHs 
peaked in 2002, and the number of RSVHs peaked in 1999. 
The proportion of all-cause hospital admissions in infants 
and children with CLDI did not change significantly over 
this time period (P = 0.146) (Figure 3).
The predicted rates are based on the fitted regression 
model with linear time trend and seasonal indicator terms. 
The predicted rate of RSVH among children with CLDI 
in the first quarter of 1998 is 93.78 per million children, 
while the predicted rate of RSVH in the first quarter of 
2008 is 49.06. Over the 11-year period, the predicted rate of 
RSVH dropped significantly by 48% (P = 0.013) (Figure 1). 
The predicted rate of RSVH/ABH declined by 32% over the 
11-year period, though this was not statistically significant 
(P = 0.102) (Figure 2).
Discussion
CLDI is the most common form of chronic lung disease in 
children in the USA.1 Northway and coworkers first described 
CLDI, which they called bronchopulmonary dysplasia, 
in 19 preterm infants who were born at approximately 32 
weeks gestation and weighed a mean of 2000 g.10 In the 
ensuing four decades a variety of measures to prevent and 
treat respiratory distress syndrome and CLDI in premature 
infants (eg, antenatal steroids, surfactant replacement, and a 
more conservative approach to respirator support) have been 
introduced.1 These improvements have resulted in changes 
in the clinical and pathologic characteristics of pulmonary 
involvement but have not produced a decrease in CLDI or 
CLDIHs, primarily because increasingly smaller premature 
infants are surviving. The average gestational age and birth 
weight of premature infants with CLDI has continued to 
decrease over the past four decades to a mean gestational 
age of 27 weeks and a birth weight of ,1000 g.1 The find-
ings from this 11-year cohort study suggest that RSVHs 
in children younger than 2 years with CLDI have steadily 
decreased even while all-cause hospitalizations in this high-
risk population remained unchanged.
Because RSV testing is not performed in up to 30% of 
suspected RSV cases,11 we re-analyzed the data using an 
expanded definition of disease that included acute bron-
chitis and bronchiolitis. Using the expanded definition, 
we observed comparable (but not statistically significant) 
declines in annual rates of hospitalizations. Therefore, we 
found no evidence that potential misclassification of RSV 
or frequency of RSV testing played an important role in the 
trends we observed.
The reasons for the overall decrease in RSVHs/ABHs in 
infants with CLDI are not well understood and are probably 
multifactorial. Potential explanations include improved neo-
natal intensive care unit and outpatient management of CLDI, 
and increased public awareness with improved protection of 
these infants from RSV illness. The increased uptake of the 
recommendations of the Committee on Infectious Diseases 
for use of palivizumab in preterm infants with CLDI may 
also play a role. Palivizumab, used for immunoprophylaxis 
for the prevention of serious RSV disease, was first licensed 
in 1998. In a multinational, randomized, placebo-controlled 
study, palivizumab was observed to reduce RSVH in pre-
term infants with CLDI by 39%. Common adverse events 
reported in this trial included fever, nervousness, injection 
site reaction, and diarrhea.12
The strengths of this study included its large sample size, 
record-based data collection, a broad geographic scope, and 
Table 1 Characteristics of CLDi children younger than 2 years 
with  rsVh  or  rsVh/ABh  between  1998  and  2008,  national 
hospital Discharge survey
RSVH RSVH/ABH
Number Percentagea Number Percentagea
Age
,3 months 2426 23% 3323 14%
3–6 months 3404 32% 10,035 44%
.6 months  
to ,2 years
4792 45% 9841 42%
Gender
Male 6922 65% 14,640 63%
Female 3700 35% 8559 37%
Race
White 4696 44% 10,615 46%
Black 2670 25% 5245 23%
Other/ 
Unknown
3256 31% 7339 32%
Region
northeast 2494 23% 5294 23%
Midwest 2290 22% 6915 30%
south 1701 16% 3486 15%
West 4137 39% 7504 32%
Medicaid
Yes 6759 64% 16,402 71%
no 3863 36% 6797 29%
Total 10,622 100% 23,199 100%
Note: aTotals may not equal 100% due to rounding.
Abbreviations: CLDi, chronic lung disease of infancy; rsVh, respiratory syncitial 
virus hospitalization; rsVh/ABh, respiratory syncitial virus and acute bronchitis and 
acute bronchiolitis hospitalization.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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a prolonged period of surveillance (11 respiratory   disease 
seasons). Limitations included our inability to validate the 
type of RSV testing used to assign a diagnosis of RSV . 
However, a recent study determined that RSVH discharge 
data correlate well with RSV testing data, regardless of the 
type of testing used.13 While it is not completely certain what 
proportion of infants with CLDI receive palivizumab, recent 
data from Canadian and US registries suggest that palivi-
zumab has been increasingly used for RSV prophylaxis in 
infants with CLDI since it was first launched in 1998.14,15
In conclusion, this study demonstrated a steady decrease 
in the yearly incidence rates of RSV-associated respiratory 
disease in infants and young children with CLDI over 11 suc-
cessive respiratory disease seasons. Reasons for this decrease 
are most likely multifactorial. Further study is warranted to 
explore these findings.
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